Pharmco/Toxicogenomics:

QPS's genomic biomarker team offers pharmacogenomics and toxicogenomics services to help identify and validate new molecular signatures for assessing drug's mechanism of action, signaling pathway, toxicity prediction, dosing optimization or disease progression and drug response monitoring. Specifically, two types of technology platforms are used:
" Quantitative RT-PCR (qRT-PCR) analysis using TaqMan® Platform in a 96-well microplate format or the ABI's TaqMan® Low Density Arrays (TLDAs).
" Global RNA Expression profiling using Affymetrix GeneChip® Microarray Platform.

We are highly skilled and experienced in analyzing patient's blood RNA expression profile by which drug-specific adverse effects may be better managed.

Genomic Biomarkers:

For preclinical drug development genomic biomarkers, such as CpG methylation patterns or RNA expression profiling, will provide new surrogate biomarkers for drug efficacy and drug safety evaluation.